TuHURA Biosciences’ (HURA) “Buy” Rating Reiterated at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports.

HURA has been the topic of a number of other reports. Citizens Jmp reissued a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $9.50.

Check Out Our Latest Analysis on HURA

TuHURA Biosciences Stock Down 4.3%

Shares of HURA opened at $1.33 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $3.43. The stock has a market capitalization of $84.76 million, a price-to-earnings ratio of -2.66 and a beta of -0.23. The stock has a fifty day moving average of $1.90 and a 200-day moving average of $2.00.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. As a group, sell-side analysts anticipate that TuHURA Biosciences will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of TuHURA Biosciences in the second quarter worth $1,615,000. Fifth Third Bancorp acquired a new stake in TuHURA Biosciences in the third quarter valued at $1,095,000. Cetera Investment Advisers bought a new position in TuHURA Biosciences during the 1st quarter worth $251,000. Bank of New York Mellon Corp bought a new position in TuHURA Biosciences during the 2nd quarter worth $285,000. Finally, WealthShield Partners LLC bought a new position in TuHURA Biosciences during the 2nd quarter worth $214,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

(Get Free Report)

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

Featured Articles

Analyst Recommendations for TuHURA Biosciences (NASDAQ:HURA)

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.